Trial Profile
A phase II Trial evaluating effects of Ibrutinib in patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2015
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 02 Dec 2015 New trial record